Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Satellos Bioscience Inc. (T.MSL) had Income from Continuous Operations of -34.52M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-34.77M |
|
-- |
|
-- |
|
-- |
|
-36.98M |
|
-- |
|
-34.52M |
|
-34.52M |
|
-34.52M |
|
|
Income from Continuous Operations |
-34.52M |
-34.52M |
|
-34.52M |
|
-36.98M |
|
-36.98M |
|
14.60M |
|
14.60M |
|
-2.38 |
|
-2.38 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
44.57M |
|
-- |
|
-- |
|
-- |
|
5.74M |
|
38.83M |
|
38.83M |
|
38.83M |
|
15.46M |
|
| Cash Flow Statement Financials | |
-32.98M |
|
-13.16M |
|
3.13M |
|
56.01M |
|
13.70M |
|
-42.31M |
|
4.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-32.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-88.90% |
|
-88.90% |
|
-77.46% |
|
-88.90% |
|
2.51 |
|
-2.26 |
|
-2.26 |
|